OverviewSuggest Edit

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. Its non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure.
Ardelyx lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. 

TypePublic
Founded2007
HQFremont, US
Websiteardelyx.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2019)88(+3%)
Job Openings19
Revenue (FY, 2019)$5.3 M(+103%)
Share Price (Nov 2020)$5.7 (-1%)
Cybersecurity ratingAMore

Key People/Management at Ardelyx

Mike Raab

Mike Raab

President and Chief Executive Officer, Director
Robert Blanks

Robert Blanks

Chief Regulatory Affairs & Quality Assurance Officer
Jeff Jacobs

Jeff Jacobs

Chief Scientific Officer
Elizabeth Grammer

Elizabeth Grammer

Chief Legal & Administrative Officer
David Mott

David Mott

Chairman
Geoffrey A. Block

Geoffrey A. Block

Director
Show more

Ardelyx Office Locations

Ardelyx has offices in Fremont and Waltham
Fremont, US (HQ)
34175 Ardenwood Blvd
Waltham, US
200 West St 4th floor
Show all (2)

Ardelyx Financials and Metrics

Ardelyx Revenue

Ardelyx's revenue was reported to be $5.28 m in FY, 2019
USD

Revenue (Q3, 2020)

2.7m

Net income (Q3, 2020)

(18.1m)

EBIT (Q3, 2020)

(17.2m)

Market capitalization (20-Nov-2020)

515.3m

Closing stock price (20-Nov-2020)

5.7

Cash (30-Sept-2020)

91.0m

EV

477.8m
Ardelyx's current market capitalization is $515.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

31.6m24.0m42.0m2.6m5.3m

Revenue growth, %

Cost of goods sold

8.4m466.0k600.0k

Gross profit

33.6m2.1m4.7m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

9.1m7.6m5.9m18.1m30.0k172.0k18.0k3.0m1.2m1.8m2.7m

Cost of goods sold

464.0k2.0k600.0k141.0k

Gross profit

170.0k2.4m1.7m

Gross profit Margin, %

99%80%92%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

107.3m107.0m74.6m75.4m78.8m181.1m

Accounts Receivable

2.6m2.6m10.8m85.0k

Prepaid Expenses

4.9m3.2m3.8m

Inventories

1.2m5.0m3.2m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.2m)(29.6m)(112.4m)(64.3m)(91.3m)(94.9m)

Depreciation and Amortization

302.0k829.0k1.3m2.6m2.7m2.5m

Inventories

(2.3m)

Accounts Payable

831.0k(371.0k)2.1m(1.0m)(2.7m)39.0k
USDQ2, 2014

Financial Leverage

2 x
Show all financial metrics

Ardelyx Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Ardelyx Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Ardelyx Online and Social Media Presence

Embed Graph

Ardelyx News and Updates

Ardelyx to Webcast Virtual Analyst Day

FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that it will hold a virtual Analyst Day on...

Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

FREMONT, Calif., March 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results...

Global Hyperkalemia Market Report 2020; Forecast to 2022 - Featuring Profiles of Ardelyx, Astrazeneca, and Vifor Pharma

DUBLIN, Feb. 11, 2020 /PRNewswire/ -- The "Hyperkalemia Market" report has been added to ResearchAndMarkets.com's offering. This report provides exposure to the hyperkalemia market. The report also highlights current and future market potential along with a detailed analysis of the...

Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public...

Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

FREMONT, Calif., Dec. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term...

Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference

FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab, president and chief...
Show more

Ardelyx Blogs

Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Content Import Mon, 11/23/2020 - 08:01 Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Nov 23, 2020 This release is a backfill from a News Wire…

Ardelyx to Present at the Jefferies Virtual London Healthcare Conference

FREMONT, Calif. , Nov. 10, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab , president and chief executive

Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights

Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights Content Import Thu, 11/05/2020 - 08:03 Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights Nov 5, 2020 This release is a backfill from a News Wire …

Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020

--Data presented across five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia--   --Exhibitor Spotlight presentation highlights advances in the science of phosphate absorption-- FREMONT, Calif. and TOKYO , Oct.

Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020

--Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia-- FREMONT, Calif. , Oct. 22, 2020 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted,

Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020

Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020 Content Import Mon, 10/12/2020 - 08:01 Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phospha…
Show more

Ardelyx Frequently Asked Questions

  • When was Ardelyx founded?

    Ardelyx was founded in 2007.

  • Who are Ardelyx key executives?

    Ardelyx's key executives are Mike Raab, Robert Blanks and Jeff Jacobs.

  • How many employees does Ardelyx have?

    Ardelyx has 88 employees.

  • What is Ardelyx revenue?

    Latest Ardelyx annual revenue is $5.3 m.

  • What is Ardelyx revenue per employee?

    Latest Ardelyx revenue per employee is $60 k.

  • Who are Ardelyx competitors?

    Competitors of Ardelyx include STipe Therapeutics, Alentis Therapeutics and Spring Discovery.

  • Where is Ardelyx headquarters?

    Ardelyx headquarters is located at 34175 Ardenwood Blvd, Fremont.

  • Where are Ardelyx offices?

    Ardelyx has offices in Fremont and Waltham.

  • How many offices does Ardelyx have?

    Ardelyx has 2 offices.